Navigating next-generation HR+/HER2- metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression

Patrick Neven; Lieke Dullens; Sileny Han; Anne Deblander; Yannick Van Herck; Maxime Van Houdt; Hans Wildiers

doi:10.21037/tbcr-23-41

Navigating next-generation HR⁺/HER2^- metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression

Transl Breast Cancer Res. 2023 Oct 23:4:31. doi: 10.21037/tbcr-23-41. eCollection 2023.

Authors

Patrick Neven^{1

2}, Lieke Dullens³, Sileny Han^{1

2}, Anne Deblander², Yannick Van Herck⁴, Maxime Van Houdt², Hans Wildiers^{1

2}

Affiliations

¹ Department of Oncology, KU Leuven-University of Leuven, Leuven, Belgium.
² Department of Gynaecological Oncology, University Hospitals Leuven, Leuven, Belgium.
³ Master Student of Medicine, KU Leuven-University of Leuven, Leuven, Belgium.
⁴ Laboratory of Experimental Oncology, University Hospitals Leuven, Leuven, Belgium.

No abstract available

Keywords: Metastatic breast cancer (MBC); abemaciclib; cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i); hormone receptor-positive (HR+); tucidinostat.

Publication types

Editorial